At MabVax Therapeutics Holdings, Inc., we are advancing a pipeline of human monoclonal antibody products that are based on the protective immune responses generated by patients who have been immunized against targeted cancers with our proprietary vaccines.

• We plan to initiate a Phase 1 clinical trial in early 2016 with our lead fully human antibody candidate HuMab 5B1 as a therapeutic treatment for metastatic pancreatic cancer.

• We plan to initiate a Phase 1 clinical trial in early 2016 with our HuMab 5B1-based companion diagnostic product as a next-generation PET imaging agent for the diagnosis and treatment assessment of metastatic pancreatic cancer.

• We have a Phase 2-ready therapeutic cancer vaccine for the childhood cancer neuroblastoma with plans to enter the clinic in 2016. Our vaccine has been granted Orphan Drug Designation by the FDA.

• We have a robust antibody discovery platform with multiple fully developed human antibody leads to 11 targets. Our leads are developed from our exclusive license with Memorial Sloan Kettering Cancer Center.

• Members of our executive management team and board of directors all have significant experience in the development of drugs and diagnostics.

>Read More about MabVax Therapeutics

BIO CEO & Investor Conference Webcast
To Access the  Webcast  CLICK HERE
To view the presentation CLICK HERE


February 3rd, 2016
MabVax Therapeutics to Present at BIO CEO and Investor Conference
Read More >

February 1st, 2016
MabVax Therapeutics Receives FDA Authorization for Phase I Clinical Trial with 89Zr-HuMab-5B1 as PET Imaging Agent for Pancreatic Cancer
Read More >

January 19th, 2016
MabVax Therapeutics executes a Debt facility for up to $10 million dollars
Read More >

January 6th, 2016
MabVax Therapeutics Files IND for a Phase I Clinical Trial with 89Zr-HuMab-5B1 Enrollment in Trial with New PET Imaging Agent Expected to Begin in Early 2016
Read More >

January 4th, 2016
MabVax Therapeutics Announces FDA Authorization to Proceed with HuMab-5B1 in a Phase I Clinical Trial for the Treatment for Pancreatic Cancer
Read More >

HuMab 5B1 Program 

Shareholder Letter 

Fact Sheet 

Corporate Presentation 

   Sign up for Email Alerts

Be the first to get breaking news 


 Shareholder Letter: 

2015 MabVax Shareholder Letter.pdf 2015 MabVax Shareholder Letter.pdf
Size : 170.929 Kb
Type : pdf

Investor Presentation: 


Loading data...
MabVax Therapeutics

Contact Us: MabVax Therapeutics
 11588 Sorrento Valley Road Suite 20
San Diego, California, 92121   (858) - 259 - 9405
email: info@mabvax.com

  © 2015, MabVax Therapeutics. All Rights Reserved 
Privacy Policy     Terms of Use     Disclaimer     Sitemap